Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effekten av tranexamsyra vid behandling av menorragi
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences.
2016 (Swedish)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

Menorrhagia is a heavy menstrual bleeding that exceeds 80 ml during a cycle. It can also be defined as a regular heavy cycle that affects the quality of life. It affects 10 % of all women in fertile age, but is most common between the ages of 30-40 years. Symptoms are tiredness, anemia and impaired quality of life. About 50 % of the cases are idiopathic, but it can also be due to systemic illness, abnormalities in endometrium or be iatrogenic. Tranexamic acid is a well-known antifibrinolytic drug. It inhibits plasmin, resulting in a reduction of the blood loss during a cycle. It can also improve the negative impact that is connected to heavy menstruation. Common side effects are nausea and vomiting. The aim of this study was to examine the efficacy of tranexamic acid on blood loss and quality of life in women with menorrhagia. It was a literature study based on five studies from the database PubMed. All studies used reduced blood loss as a primary endpoint and impact on quality of life as a secondary endpoint. The outcome was presented with average scores for the treated groups. Two studies had a group that received tranexamic acid 3,9 g and a group that received placebo. They showed that tranexamic acid gives a statistically significant reduction of blood loss and improvement of quality of life compared to placebo. The reduction of blood loss was considered to be meaningful for the participants. Three studies, which lacked a placebo group, showed that tranexamic acid 2,0 g and 3,0 g gives a significant reduction of blood loss compared to before treatment started. They also showed an improvement in quality of life. In conclusion, treatment with tranexamic acid showed a significant effect on both blood loss and quality of life.

Place, publisher, year, edition, pages
2016. , 26 p.
Keyword [sv]
Menorragi, tranexamsyra
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:lnu:diva-52489OAI: oai:DiVA.org:lnu-52489DiVA: diva2:928093
Subject / course
Pharmacy
Educational program
Bachelor of Science Programme in Pharmacy, 180 credits
Supervisors
Examiners
Available from: 2016-05-16 Created: 2016-05-14 Last updated: 2016-05-16Bibliographically approved

Open Access in DiVA

fulltext(1222 kB)103 downloads
File information
File name FULLTEXT01.pdfFile size 1222 kBChecksum SHA-512
4f4e7fcbd93811d222eb577d34c0839c2a0f2c0e14b424e62bbdf68c6190d950a594e6935e0a2d845b9644072839068e41b07fe4c553130bfe2d1440cedb1b0e
Type fulltextMimetype application/pdf

Search in DiVA

By author/editor
Ivarsson, Veronika
By organisation
Department of Chemistry and Biomedical Sciences
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 103 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 162 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf